Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011) — Grand Rapids, Michigan

Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011) is a clinical research site located in Grand Rapids, Michigan, United States 49503.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011) has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.

Sponsors: Merck Sharp & Dohme LLC.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Grand Rapids

Browse all research sites in Michigan · View every site in Grand Rapids

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011)?

Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011) has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011) conducted?

Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011) has 1 clinical trials on record, with 1 currently active. Their work covers Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.

Is Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011) accredited by Crixeo Clinical Trials?

Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.